Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced chronic kidney disease and eventually to renal failure.
Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab / Allinovi, Marco; Cirami, Calogero Lino; Caroti, Leonardo; Antognoli, Giulia; Farsetti, Silvia; Amato, Maria Pia; Minetti, Enrico Eugenio. - In: CLINICAL KIDNEY JOURNAL. - ISSN 2048-8505. - STAMPA. - 10:(2017), pp. 625-631. [10.1093/ckj/sfw143]
Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
ALLINOVI, MARCO;CAROTI, LEONARDO;ANTOGNOLI, GIULIA;FARSETTI, SILVIA;AMATO, MARIA PIA;
2017
Abstract
Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced chronic kidney disease and eventually to renal failure.
| File | Dimensione | Formato | |
|---|---|---|---|
|
sfw143.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
547.04 kB
Formato
Adobe PDF
|
547.04 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
